Cambridge Investment Research Advisors’s Interpace Biosciences, Inc. Common Stock IDXG Stock Holding History

Cambridge Investment Research Advisors’s Portfolio IDXG Stock Details IDXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-5,490	Closed	-$27K	–	2551
2019 Q4	$27K	Buy	5,490 +780	+17%	+$5.05K	﹤0.01%	2380
2019 Q3	$37K	Buy	4,710 +235	+5%	+$1.83K	﹤0.01%	2299
2019 Q2	$32K	Buy	4,475 +2,215	+98%	+$16.2K	﹤0.01%	2169
2019 Q1	$18K	Hold	2,260	–	–	﹤0.01%	2259
2018 Q4	$18K	Sell	2,260 -1	-0%	-$12	﹤0.01%	2125
2018 Q3	$35K	Hold	2,261	–	–	﹤0.01%	2207
2018 Q2	$20K	Buy	2,261 +1	+0%	+$9	﹤0.01%	2191
2018 Q1	$20K	Hold	2,260	–	–	﹤0.01%	2131
2017 Q4	$23K	Buy	+2,260	New	+$27.3K	﹤0.01%	2091

Other funds holding IDXG

PCM

Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EIM

Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Allworth Financial Folsom, California $24.7B AUM 15.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Cambridge Investment Research Advisors's IDXG Position: Q1 2020 in Review

Cambridge Investment Research Advisors sold out of Interpace Biosciences, Inc. Common Stock (IDXG) in Q1 2020, closing a stake of 5,490 shares — an estimated $27K sold.

Cambridge Investment Research Advisors first reported a position in IDXG in Q4 2017 and held it in 9 quarters. The position peaked at $37K in Q3 2019. 15 funds tracked by Wall St. Rank hold IDXG as of Q1 2020.

Cambridge Investment Research Advisors reported no remaining Interpace Biosciences, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
Cambridge Investment Research Advisors sold 5,490 Interpace Biosciences, Inc. Common Stock shares in Q1 2020, an estimated $27K.
Cambridge Investment Research Advisors first reported a position in Interpace Biosciences, Inc. Common Stock in Q4 2017 and held it in 9 quarters.
Cambridge Investment Research Advisors's Interpace Biosciences, Inc. Common Stock position peaked at $37K in Q3 2019.
15 funds tracked by Wall St. Rank held Interpace Biosciences, Inc. Common Stock as of Q1 2020.

Based on Cambridge Investment Research Advisors's 13F filing for Q1 2020, filed 8 May 2020.